Cover Image
市場調查報告書

頭頸部腫瘤:流行病學·基於患者的市場預測,治療流程,上市藥·開發平台藥物分析

Head and Neck Cancer: Forecast

出版商 Datamonitor Healthcare 商品編碼 365175
出版日期 內容資訊 英文 71 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
頭頸部腫瘤:流行病學·基於患者的市場預測,治療流程,上市藥·開發平台藥物分析 Head and Neck Cancer: Forecast
出版日期: 2018年01月26日 內容資訊: 英文 71 Pages
簡介

本報告提供頭頸部腫瘤治療藥市場相關調查分析,提供您市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:頭頸部腫瘤

  • 摘要整理
  • 市場概要·趨勢
  • 市場定義·手法
  • Durvalumab
  • Erbitux (cetuximab)
  • Gilotrif (afatinib)
  • Javlor (vinflunine ditartrate)
  • Keytruda (pembrolizumab)
  • Multikine
  • Opdivo (nivolumab)
  • Reolysin
  • TS-1 (gimeracil/oteracil potassium/tegafur)
  • 1次調查手法

治療:頭頸部腫瘤

  • 摘要整理
  • 1次調查手法
  • 疾病定義·診斷
  • 患者區分
  • 各國治療樹
  • 目前治療選擇
  • 處方趨勢:I期·II期
  • 處方趨勢:III期
  • 處方趨勢:IV期

流行病學:頭頸部腫瘤

  • 摘要整理
  • 資訊來源·手法
  • 預測
  • 流行病學者的考察
  • 優點·缺點

上市藥:頭頸部腫瘤

  • 摘要整理
  • 產品概要
  • 產品簡介: Erbitux

開發平台:頭頸部腫瘤

  • 摘要整理
  • 臨床實驗平台概要
  • 最近中止開發的藥
  • 比較治療
  • 產品簡介 (後期) :Gilotrif
  • 產品簡介 (後期) :Javlor
  • 產品簡介 (後期) :Keytruda
  • 產品簡介 (後期) :Multikine
  • 產品簡介 (後期) :Opdivo
  • 產品簡介 (後期) :Reolysin
  • 產品簡介 (後期) :durvalumab

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: #NA

DESCRIPTION

Datamonitor Healthcare uses a patient-based approach to size the commercial potential of the SCCHN market across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). This analysis contains an assessment of key SCCHN therapies on the market and in the late-phase pipeline, a discussion of SCCHN market dynamics, and a 10-year patient-based sales forecast.

HIGHLIGHTS

Datamonitor Healthcare estimates that sales of key SCCHN drugs across the US, Japan, and five major EU markets are forecast to total $906m in

2017. The value of these markets is expected to increase to $2.8bn in

2026. The primary growth driver behind this market expansion will be the launch of PD-1/PD-L1-targeted immunotherapies for SCCHN. The projected widespread use of these treatments, in combination with their high cost, will result in a large increase in market sales.

Datamonitor Healthcare anticipates that the continued uptake of Erbitux and sales of new targeted therapy brands in SCCHN will offset potential biosimilar erosion during the forecast period.

CONTENTS

9 FORECAST: HEAD AND NECK CANCER

9 Executive Summary

10 Market Overview and Trends

25 Market Definition and Methodology

33 durvalumab

37 Erbitux (cetuximab)

42 Gilotrif (afatinib)

46 Javlor (vinflunine ditartrate)

50 Keytruda (pembrolizumab)

54 Multikine

58 Opdivo (nivolumab)

62 Reolysin

66 TS-1 (gimeracil/oteracil potassium/tegafur)

69 Primary Research Methodology

71 TREATMENT: HEAD AND NECK CANCER

71 Executive Summary

72 Primary Research Methodology

74 Disease Definition and Diagnosis

81 Patient Segmentation

84 Current Treatment Options

89 Prescribing Trends

110 EPIDEMIOLOGY: HEAD AND NECK CANCER

110 Executive Summary

111 Disease Background

113 Methodology

123 Forecast

131 Epidemiologist Insight

132 Strengths and Limitations

135 Bibliography

138 Appendix: Additional Sources

139 MARKETED DRUGS: HEAD AND NECK CANCER

139 Executive Summary

140 Product Overview

141 Product profile: Erbitux

152 PIPELINE: HEAD AND NECK CANCER

152 Executive Summary

153 Clinical Pipeline Overview

157 Recently Discontinued Drugs

160 Comparator Therapy

163 Product profile (late stage): Gilotrif

171 Product profile (late stage): Javlor

178 Product profile (late stage): Keytruda

189 Product profile (late stage): Multikine

197 Product profile (late stage): Opdivo

206 Product profile (late stage): Reolysin

213 Product profile (late stage): durvalumab

LIST OF FIGURES

  • 11 Figure 1: SCCHN drug sales in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 15 Figure 2: SCCHN drug sales in the US, Japan, and five major EU markets, by status ($m), 2015-24
  • 17 Figure 3: SCCHN drug sales in the US, by status ($m), 2015-24
  • 19 Figure 4: SCCHN drug sales in Japan, by status ($m), 2015-24
  • 21 Figure 5: SCCHN drug sales in the five major EU markets, by status ($m), 2015-24
  • 27 Figure 6: Methodology flow
  • 29 Figure 7: Price sources and calculations, by country
  • 34 Figure 8: Durvalumab sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 38 Figure 9: Erbitux sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 43 Figure 10: Gilotrif sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 47 Figure 11: Javlor sales forecast for SCCHN in the five major EU markets, by country ($m), 2015-24
  • 51 Figure 12: Keytruda sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 55 Figure 13: Multikine sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 59 Figure 14: Opdivo sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 63 Figure 15: Reolysin sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 67 Figure 16: TS-1 sales forecast for SCCHN in Japan ($m), 2015-24
  • 76 Figure 17: HPV screening rates and outcomes among SCCHN patients, by country
  • 82 Figure 18: Proportion of prevalent SCCHN patients in each stage of disease, by country
  • 90 Figure 19: Proportion of Stage I and Stage II SCCHN patients receiving each treatment type, by country
  • 91 Figure 20: Percentage of Stage III SCCHN patients receiving each treatment type, by country
  • 92 Figure 21: Percentage of Stage III SCCHN patients receiving neoadjuvant therapy, adjuvant therapy, or both, by country
  • 93 Figure 22: Top three regimens used in the adjuvant treatment of Stage III SCCHN patients, by country
  • 95 Figure 23: Percentage of Stage IV SCCHN patients receiving each treatment type, by country
  • 96 Figure 24: Top three regimens used in the first-line treatment of Stage IV SCCHN patients who receive pharmacological therapy without surgery, by country
  • 97 Figure 25: Percentage of Stage IV SCCHN patients who progress from first- to second-line therapy or from second- to thirdline therapy, by country
  • 99 Figure 26: Top three regimens used for the second-line treatment of Stage IV SCCHN patients, by country
  • 101 Figure 27: Percentage of local relapse SCCHN patients receiving each treatment type, by country
  • 102 Figure 28: Top three regimens used in the first-line treatment of local relapse SCCHN patients receiving pharmacological therapy without surgery, by country
  • 103 Figure 29: Top three regimens used in the second-line treatment of local relapse SCCHN patients, by country
  • 104 Figure 30: Percentage of distant relapse SCCHN patients receiving each treatment type, by country
  • 105 Figure 31: Top three regimens used in the first-line treatment of distant relapse SCCHN patients who receive pharmacological therapy without surgery, by country
  • 107 Figure 32: Top three regimens used in the second-line treatment of distant relapse SCCHN patients, by country
  • 125 Figure 33: Trends in incident cases of HNC in the US, Japan, and five major EU markets, 2016-36
  • 127 Figure 34: Absolute change in incident cases of HNC in the US, Japan, and five major EU markets, 2016-36
  • 129 Figure 35: Age-specific trends in incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016-36
  • 146 Figure 36: Erbitux for head and neck cancer - SWOT analysis
  • 147 Figure 37: Datamonitor Healthcare's drug assessment summary of Erbitux for head and neck cancer
  • 148 Figure 38: Datamonitor Healthcare's drug assessment summary of Erbitux for head and neck cancer
  • 167 Figure 39: Gilotrif for head and neck cancer - SWOT analysis
  • 168 Figure 40: Datamonitor Healthcare's drug assessment summary of Gilotrif for head and neck cancer
  • 169 Figure 41: Datamonitor Healthcare's drug assessment summary of Gilotrif for head and neck cancer
  • 174 Figure 42: Javlor for head and neck cancer - SWOT analysis
  • 175 Figure 43: Datamonitor Healthcare's drug assessment summary of Javlor for head and neck cancer
  • 176 Figure 44: Datamonitor Healthcare's drug assessment summary of Javlor for head and neck cancer
  • 183 Figure 45: Keytruda for head and neck cancer - SWOT analysis
  • 184 Figure 46: Datamonitor Healthcare's drug assessment summary of Keytruda for head and neck cancer
  • 185 Figure 47: Datamonitor Healthcare's drug assessment summary of Keytruda for head and neck cancer
  • 193 Figure 48: Multikine for head and neck cancer - SWOT analysis
  • 194 Figure 49: Datamonitor Healthcare's drug assessment summary of Multikine for head and neck cancer
  • 195 Figure 50: Datamonitor Healthcare's drug assessment summary of Multikine for head and neck cancer
  • 201 Figure 51: Opdivo for head and neck cancer - SWOT analysis
  • 202 Figure 52: Datamonitor Healthcare's drug assessment summary of Opdivo for head and neck cancer
  • 203 Figure 53: Datamonitor Healthcare's drug assessment summary of Opdivo for head and neck cancer
  • 209 Figure 54: Reolysin for head and neck cancer - SWOT analysis
  • 210 Figure 55: Datamonitor Healthcare's drug assessment summary of Reolysin for head and neck cancer
  • 211 Figure 56: Datamonitor Healthcare's drug assessment summary of Reolysin for head and neck cancer
  • 217 Figure 57: Durvalumab for head and neck cancer - SWOT analysis
  • 218 Figure 58: Datamonitor Healthcare's drug assessment summary of durvalumab for head and neck cancer
  • 219 Figure 59: Datamonitor Healthcare's drug assessment summary of durvalumab for head and neck cancer

LIST OF TABLES

  • 12 Table 1: SCCHN drug sales in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 16 Table 2: SCCHN drug sales in the US, Japan, and five major EU markets, by brand and status ($m), 2015-24
  • 18 Table 3: SCCHN drug sales in the US, by brand and status ($m), 2015-24
  • 20 Table 4: SCCHN drug sales in Japan, by brand and status ($m), 2015-24
  • 22 Table 5: SCCHN drug sales in the five major EU markets, by brand and status ($m), 2015-24
  • 25 Table 6: Summary of drug classes, molecules, and brands included in the SCCHN patient-based forecast
  • 30 Table 7: Exchange rates used for calculating prices
  • 30 Table 8: Patent expiry dates for key marketed brands in SCCHN, by region
  • 31 Table 9: Estimated approval dates of key late-stage pipeline products in SCCHN, by region
  • 35 Table 10: Durvalumab sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 36 Table 11: Durvalumab patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
  • 39 Table 12: Erbitux sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 40 Table 13: Erbitux patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
  • 44 Table 14: Gilotrif sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 45 Table 15: Gilotrif patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
  • 48 Table 16: Javlor sales forecast for SCCHN in the five major EU markets, by country ($m), 2015-24
  • 49 Table 17: Javlor patient numbers for SCCHN in the five major EU markets, by country, 2015-24
  • 52 Table 18: Keytruda sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 53 Table 19: Keytruda patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
  • 56 Table 20: Multikine sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 57 Table 21: Multikine patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
  • 60 Table 22: Opdivo sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 61 Table 23: Opdivo patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
  • 64 Table 24: Reolysin sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • 65 Table 25: Reolysin patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
  • 67 Table 26: TS-1 sales forecast for SCCHN in Japan ($m), 2015-24
  • 68 Table 27: TS-1 patient numbers for SCCHN in Japan, 2015-24
  • 69 Table 28: Physicians surveyed for the squamous cell carcinoma of the head and neck primary research study, 2015
  • 72 Table 29: Physicians surveyed for the head and neck cancer primary research study, 2017
  • 77 Table 30: Oral cavity and pharynx cancer five-year survival rates, by stage at diagnosis, 2007-13
  • 81 Table 31: TNM stage classification
  • 85 Table 32: Leading treatments for SCCHN
  • 111 Table 33: Head and neck cancer site codes according to ICD-10
  • 117 Table 34: Cancer registry databases used as a source of HNC incidence data, by country
  • 119 Table 35: Forecasting methodology for HNC incidence, by country, age group, and gender
  • 121 Table 36: Sources of survival data used to estimate HNC prevalence, by country/region
  • 124 Table 37: Diagnosed incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016-36
  • 128 Table 38: Age-specific incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016
  • 130 Table 39: Gender-specific incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016
  • 133 Table 40: Validation of forecast estimates against benchmark estimates
  • 140 Table 41: Key marketed drugs for head and neck cancer
  • 142 Table 42: Erbitux drug profile
  • 144 Table 43: Erbitux pivotal trial data in head and neck cancer
  • 153 Table 44: Late-stage pipeline products in development for head and neck cancer
  • 157 Table 45: Late-stage compounds that were recently discontinued for head and neck cancer
  • 161 Table 46: Erbitux drug profile
  • 164 Table 47: Gilotrif drug profile
  • 165 Table 48: Gilotrif Phase III trials in head and neck cancer
  • 166 Table 49: Gilotrif Phase III data in head and neck cancer
  • 172 Table 50: Javlor drug profile
  • 173 Table 51: Javlor Phase III trials in head and neck cancer
  • 179 Table 52: Keytruda drug profile
  • 180 Table 53: Keytruda Phase III trials in head and neck cancer
  • 182 Table 54: Keytruda topline early-phase data in head and neck cancer
  • 186 Table 55: Overview of Phase Ib trial data for Keytruda in PD-L1-positive head and neck cancer patients
  • 190 Table 56: Multikine drug profile
  • 191 Table 57: Multikine Phase III trials in head and neck cancer
  • 192 Table 58: Overview of Phase II trial data for Multikine in head and neck cancer
  • 198 Table 59: Opdivo drug profile
  • 199 Table 60: Ongoing Opdivo Phase III trials in head and neck cancer
  • 200 Table 61: Opdivo Phase III data in head and neck cancer
  • 207 Table 62: Reolysin drug profile
  • 208 Table 63: Reolysin Phase III data in head and neck cancer
  • 214 Table 64: Durvalumab drug profile
  • 215 Table 65: Durvalumab Phase III and pivotal Phase II trials in head and neck cancer

 

Back to Top